Notice names this product. Baxter Healthcare’s Clindamycin Phosphate in 0 is named in FDA Class II recall D-0816-2026. Your particular item is not yet verified. Compare the identifiers and exclusions in the notice before deciding whether it applies. Agency-reported hazard: CGMP Deviations Identifying details: Lot # NC193689, Exp Date: 10/16/2027.. Units affected: N/A. Status: Ongoing.
This notice names a product; your particular item is not yet verified. Compare every applicable model, serial, lot, production-date or model-year boundary below.
Clindamycin Phosphate in 0.9% Sodium Chloride Injection, 600 mg per 50 mL (12 mg/mL), 50 mL Single-Dose GALAXY Container, Rx only, Sterile Nonpyrogenic, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-9549-50.
Still to verify: match the label on your item with the full official notice, including any exclusions, tables and photos. Some identifiers appear only on the agency website and are absent from this data feed. A missing field does not mean all versions are affected.
If your lot or date falls outside a stated range, this notice has not established that your item is affected. This is not a finding about other recalls or product safety.
CGMP Deviations
Company / brand: Baxter Healthcare recalls
Affected product: Clindamycin Phosphate in 0 recall status
Official ID D-0816-2026 · Official record ↗
See all Baxter Healthcare recalls →
Found something wrong or missing? Report a data error.
Compiled from connected official public-domain government data. Sources last checked October 22, 2026 at 12:00 PM UTC.